Breast cancer - Risk Factors and Prevention Strategies

Breast Cancer: Risk Factors and Prevention Introduction Breast cancer develops through a combination of factors: some we cannot control (like genetics or age), while others are modifiable through lifestyle choices or medical interventions. Understanding these risk factors helps clinicians identify high-risk patients, counsel them appropriately, and offer targeted prevention strategies. This chapter examines the major categories of risk factors and discusses evidence-based approaches to prevention. Hormonal and Reproductive Factors Estrogen exposure is central to breast cancer development, which explains why hormonal factors play such a large role in risk. The longer a woman is exposed to estrogen, the greater her risk. Menarche and Menopause Early menarche (menstruation before age 12) and late menopause (after age 51) both increase breast cancer risk because they extend the duration of monthly hormonal cycling. Each year of earlier menarche or later menopause increases cumulative estrogen exposure, raising incidence. This is why postmenopausal women generally have lower risk than premenopausal women of the same age. Pregnancy and Lactation Early pregnancy offers significant protection against breast cancer. However, this protective effect depends on timing: a first pregnancy before age 35 confers lasting risk reduction of about 70%. Surprisingly, if a woman has her first pregnancy after age 35, this protective effect disappears entirely. This occurs because pregnancy temporarily increases breast cancer risk during the premenopausal years, and once this window closes with advancing age, the long-term protective benefit is lost. Breastfeeding adds additional protection beyond pregnancy itself. Each 12 months of lactation reduces breast cancer risk by approximately 4%. The mechanism likely involves reduced estrogen levels and changes in breast tissue differentiation during lactation. Hormone Replacement Therapy (HRT) This is a critical distinction for exam purposes: the type of HRT matters enormously. Combined HRT (estrogen + progesterone) roughly doubles breast cancer risk after 6–7 years of use. This was a major finding from the Women's Health Initiative study and changed clinical practice. Estrogen-only HRT does not increase breast cancer risk but raises endometrial cancer risk, so it is prescribed only after hysterectomy (when the uterus is not present and endometrial cancer is not a concern). Lifestyle Factors Lifestyle modifications offer a modifiable path to risk reduction, with studies suggesting that lifestyle changes could prevent approximately 25% of breast cancers globally. Alcohol and Weight Alcohol increases breast cancer risk even at light consumption levels, with heavy drinking carrying the greatest increase. The mechanism involves interference with estrogen metabolism and increased blood estrogen concentrations. Obesity contributes to approximately 7% of breast cancer cases, particularly in postmenopausal women. Central adiposity (fat concentrated around the abdomen) is especially risky because abdominal fat tissue actively produces estrogen. Rapid weight gain in adulthood carries higher risk than stable obesity. Physical Activity Physical inactivity accounts for roughly 10% of breast cancer cases. Regular moderate-intensity physical activity (at least 150 minutes weekly) reduces risk, with high levels of activity reducing risk by about 14%. Notably, prolonged sitting increases not just incidence but also breast cancer mortality, highlighting the importance of movement even for women already diagnosed. Smoking Long-term smokers experience a 35–50% increased risk, with risk rising based on earlier age of initiation and greater daily consumption. <extrainfo>While less commonly discussed than smoking's link to lung cancer, this association is well-established.</extrainfo> Diet A diet rich in vegetables, fruits, whole grains, and legumes, with adequate soluble fiber intake, supports risk reduction. <extrainfo>Some evidence suggests that consuming citrus fruit is linked to a 10% lower risk, and that marine omega-3 polyunsaturated fatty acids and regular soy consumption may reduce risk, though these associations are less firmly established than the benefits of overall dietary pattern.</extrainfo> In contrast, high-fat diets and elevated cholesterol may increase risk, though this relationship requires further clarification. <extrainfo>Other lifestyle factors with emerging evidence include shift work and late-night eating, which may disrupt circadian rhythms and sleep quality, and exposure to certain environmental chemicals such as polychlorinated biphenyls, polycyclic aromatic hydrocarbons, and organic solvents.</extrainfo> Genetic Factors Approximately 10% of breast cancers are attributable to inherited genetic predisposition. Understanding genetic risk is crucial for identifying candidates for intensive screening or preventive interventions. Major Susceptibility Genes The most important genes are the breast cancer susceptibility genes BRCA1 and BRCA2. Pathogenic variants in either gene confer approximately a 70% lifetime risk of breast cancer by age 80 and a 33% risk of ovarian cancer. Women with these mutations are considered very high-risk and are candidates for aggressive prevention strategies. Other notable genes include: PALB2: Mutations increase breast cancer risk by roughly 50% TP53 (Li–Fraumeni syndrome): Tumor-suppressor mutations that significantly elevate risk PTEN (Cowden syndrome): Another tumor-suppressor pathway PALB1: Additional tumor-suppressor involvement Family History Having a first-degree relative (mother, sister, daughter) with breast cancer increases personal risk by 30–50%, depending on the relative's age at diagnosis and whether the familial mutation is known. Medical and Other Factors Benign Breast Conditions Women with benign breast lesions, particularly atypical ductal hyperplasia (abnormal cell growth), have elevated risk. Fibrocystic changes (common, non-cancerous changes in breast tissue) also contribute modestly to risk. Systemic Conditions Diabetes and autoimmune diseases such as systemic lupus erythematosus are associated with higher breast cancer risk, likely through chronic inflammation and altered immune function. Prior Radiation Exposure High-dose ionizing radiation exposure before age 30 markedly increases breast cancer risk. This includes exposure from chest fluoroscopy (a diagnostic technique formerly used for tuberculosis), radiation therapy for Hodgkin lymphoma, or atomic bomb radiation. The younger the age at exposure, the higher the long-term risk. This risk can take decades to manifest. Prevention Strategies Prevention of breast cancer operates at three levels: primary prevention (reducing risk in the general population), secondary prevention (detecting early disease in high-risk individuals), and chemoprevention (using medications to reduce incidence in high-risk women). Lifestyle Modification The most broadly applicable prevention strategy involves lifestyle changes applicable to all women: Limit alcohol to ≤1 drink per day Maintain healthy weight (BMI < 25 kg/m²), particularly important after menopause Engage in ≥150 minutes of moderate-intensity physical activity weekly Avoid smoking Breastfeed if possible Follow a diet rich in vegetables, fruits, whole grains, and legumes Together, these modifications could prevent roughly 25% of breast cancers worldwide. Pharmacologic Prevention (Chemoprevention) Selective Estrogen Receptor Modulators (SERMs) Tamoxifen and raloxifene decrease breast cancer incidence in high-risk women. These medications block estrogen effects in breast tissue while maintaining some estrogenic effects in bone and other tissues. However, they carry important downsides: increased risk of blood clots (deep vein thrombosis and pulmonary embolism) and endometrial cancer (for tamoxifen). SERMs are not recommended for average-risk women but are offered to high-risk women older than 35 years. Notably, the protective effect continues for at least five years after stopping therapy, providing durable benefit. Aromatase Inhibitors (AIs) Exemestane and anastrozole may be more effective than SERMs, particularly for postmenopausal women, and do not increase the risk of endometrial cancer or blood clots. This makes them an attractive option for postmenopausal women at high risk. Risk-Reducing Surgery Prophylactic Mastectomy Bilateral prophylactic mastectomy (removal of both breasts before cancer develops) reduces breast cancer incidence by more than 95% in high-risk women, particularly those with BRCA1/2 mutations. In women with known genetic predisposition, it also reduces mortality from breast cancer. However, it is not recommended for women at average risk because it does not improve survival and carries significant physical and psychological morbidity. In some cases, women with a diagnosis of breast cancer in one breast may consider contralateral risk-reducing mastectomy to prevent cancer in the second breast, though its effect on overall survival remains uncertain. Salpingo-Oophorectomy Removal of the fallopian tubes and ovaries (salpingo-oophorectomy) lowers the risk of hormone-driven breast cancer in premenopausal high-risk women by reducing circulating estrogen and preventing ovarian cancer. Screening and Early Detection Regular mammographic screening detects tumors when they are smaller and less likely to have spread, improving prognosis. For women with pathogenic BRCA1/2 mutations (very high-risk), annual MRI plus mammography is recommended for breast cancer screening, as these women are at particular risk for aggressive, rapidly growing cancers that standard mammography alone might miss. Summary Table of Key Prevention Strategies | Strategy | Population | Effectiveness | Key Considerations | |----------|-----------|---------------|--------------------| | Lifestyle modification | All women | Prevents 25% of cases | Achievable for most; low cost | | Tamoxifen/Raloxifene | High-risk women ≥35 years | Reduces incidence | Risk of blood clots, endometrial cancer; benefit lasts ≥5 years post-therapy | | Aromatase inhibitors | Postmenopausal high-risk women | Reduces incidence; may be more effective than SERMs | No endometrial cancer or thrombosis risk | | Prophylactic mastectomy | Very high-risk women (BRCA carriers) | >95% risk reduction | Irreversible; significant psychological impact; not recommended for average risk | | Screening (MRI + mammography) | BRCA carriers | Detects early disease | Improves prognosis through early detection |